Aramchol is under clinical development by Galmed Pharmaceuticals and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Aramchol’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 26 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Aramchol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Aramchol overview

Aramchol is under development for the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease and hepatic insufficiency, fibrosis. The drug candidate is administered through the oral route in the form of tablet. Aramchol is a conjugate of cholic acid and arachidic acid and acts by targeting Stearoyl-Coenzyme A Desaturase 1 (SCD1) and ABCA1 transporter. It was also under development for the treatment of cholesterol gallstones and HIV-associated lipodystrophy.

Galmed Pharmaceuticals overview

Galmed Pharmaceuticals, a subsidiary of Galmed International Ltd, clinical stage drug development biopharmaceutical company for liver, metabolic, and inflammatory diseases. The company focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with nonalcoholic steatohepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel.

Quick View Aramchol LOA Data

Report Segments
  • Innovator
Drug Name
  • Aramchol
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.